United Therapeutics Corporation (UTHR)
Quick ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 1,207,700 | 961,200 | 894,800 | 738,700 | 738,400 |
| Short-term investments | US$ in thousands | 1,801,300 | 1,908,200 | 1,035,900 | 1,096,300 | 747,500 |
| Receivables | US$ in thousands | 278,900 | 220,400 | 198,700 | 157,400 | 151,400 |
| Total current liabilities | US$ in thousands | 804,400 | 343,200 | 305,400 | 323,300 | 463,000 |
| Quick ratio | 4.09 | 9.00 | 6.97 | 6.16 | 3.54 |
December 31, 2023 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($1,207,700K
+ $1,801,300K
+ $278,900K)
÷ $804,400K
= 4.09
The quick ratio of United Therapeutics Corp has exhibited fluctuating trends over the past five years. In 2023, the quick ratio stood at 4.28, a significant decrease from the previous year's ratio of 9.55. Despite this decrease, the company's quick ratio remains relatively strong, indicating that United Therapeutics Corp has sufficient liquid assets to cover its current liabilities. The peak quick ratio of 9.55 in 2022 suggests a robust liquidity position, reflecting a substantial increase in the company's ability to meet short-term obligations without relying on inventory. Overall, the quick ratio of United Therapeutics Corp has shown variability but generally indicates a healthy liquidity position over the years.
Peer comparison
Dec 31, 2023